Business Context and Reporting Period
This Form 8-K Current Report was filed by LIFECORE BIOMEDICAL, INC. on May 14, 2024, covering events occurring on May 8, 2024 and May 10, 2024. The Company is incorporated in Delaware and its common stock trades on the NASDAQ Global Select Market under the symbol LFCR.
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, or operating margins. The report focuses exclusively on debt restructuring and regulatory compliance status.
- Debt Instrument: Establishment of a "First-In-Last-Out" (FILO) tranche of revolving loans under the Amended ABL Credit Agreement.
- Interest Rate: FILO Loans bear interest at SOFR plus 4.25%.
- Repayment Priority: Repayments are applied first to non-FILO loans, then to FILO loans.
- Amortization: The FILO Cap will be reduced monthly commencing October 1, 2025.
Material Changes
The filing reports two material developments:
- Amendment to Credit Agreement: On May 10, 2024, the Company, along with Curation Foods, Inc. and Lifecore Biomedical Operating Company, Inc., entered into a Seventh Amendment to its Credit Agreement with BMO Bank N.A. This amendment created a FILO tranche to provide additional liquidity flexibility, subject to a variable cap.
- Nasdaq Delisting Proceedings: The Company is currently in a delisting process initiated by Nasdaq on February 13, 2024, due to failure to timely file periodic financial reports (Listing Rule 5250(c)(1)). On May 8, 2024, the Nasdaq Hearings Panel requested additional information to consider a further stay of suspension or delisting. The Company provided this information on May 10 and May 14, 2024, but a decision has not yet been issued.
Outlook, Risks, and Contingencies
Management Commentary and Outlook: The Company states it is working diligently to complete delinquent periodic reports and intends to file them as promptly as possible to regain compliance. Management anticipates a decision from the Nasdaq Panel regarding a further stay is forthcoming.
Risks and Contingencies:
- Delisting Risk: There is no assurance that the Company will file delinquent reports before any stay expires or that the Panel will grant a further stay. Failure to regain compliance could result in the suspension or delisting of securities from Nasdaq.
- Debt Obligations: The FILO Cap reductions starting in October 2025 may require mandatory repayment of outstanding revolving loans if the cap reduction causes total credit outstanding to exceed the maximum borrowing amount.
- Forward-Looking Statements: Actual results may differ materially due to the Company's ability to respond to Nasdaq inquiries and the timing of future filings.
Investor Verification Checklist
- Verify the status of the Company's delinquent periodic reports (e.g., 10-K, 10-Q) and whether they have been filed with the SEC.
- Monitor the Nasdaq Hearings Panel's decision regarding the request for a further stay of delisting action.
- Review the full text of the Seventh Amendment to the Credit Agreement (Exhibit 10.1) to understand the specific terms of the FILO Cap and repayment triggers.
- Assess the Company's liquidity position given the potential for mandatory debt repayment starting October 2025.